A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic ...
from Google Alert - health https://ift.tt/32B6JqV
via IFTTT
0 comments:
Post a Comment